戻る
Nykode Therapeutics AS (VACBF)価格
VACBF 株価推移チャート
VACBF 収入
Nykode Therapeutics AS
$0.15
0%
$0
終値： Jan 23, 16:00:00 GMT-5
$0.15
0%
$0
アフターマーケット：Jan 23, 20:00:00 GMT-5
最新の利益結果: Q4 '24
報告済み: 2025-02-26
歴史的収益
四半期
年次
EPS
収入
Earnings FAQ
VACBFの最近の1株当たり利益（EPS）は予想と比較してどうでしたか？
Nykode Therapeutics AS VACBFの前四半期の収益はどうでしたか？
Nykode Therapeutics ASの収益見積もりはいくらですか？
Nykode Therapeutics ASの収益品質スコアはどれくらいですか？
Nykode Therapeutics ASはいつ収益を報告しますか？
Nykode Therapeutics ASの予想収益はいくらですか？
Nykode Therapeutics ASは収益予想を上回りましたか？
主要データ
前終値
$0.1557
始値
$1.5
当日レンジ
$0.1557 - $1.5
52週レンジ
$0.1557 - $1.5
取引高
6.6K
平均取引高
39
1株当たり利益(TTM)
-0.03
配当利回り
--
時価総額
$50.8M
NYKODE THERAPEUTICS ASAとは何ですか？
Nykode Therapeutics ASA is a clinical-stage biopharmaceutical company which engages in discovering and developing of novel immunotherapies. The company is headquartered in Oslo, Oslo and currently employs 62 full-time employees. The company went IPO on 2020-01-27. Nykode uses its vaccine technology platform to generate therapeutics in disease indications with unmet medical need. The firm develops next generation vaccines for clinical use, based on a deep understanding of immunological principles. Nykode Therapeutics’ main product candidates are VB10.16 and VB10.NEO. VB10.16 is a therapeutic cancer vaccine against HPV16-related cancers. VB10. NEO is a therapeutic cancer neoantigen vaccine. The firm also has two universal COVID-19 vaccine candidates in development.